Review: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis

Abstract

Endotoxin is considered to be a systemic (immunological) stressor eliciting a prolonged activation of the hypothalamo-pituitary-adrenal (HPA) axis. The HPA-axis response after an endotoxin challenge is mainly due to released cytokines (IL-1, IL-6 and TNF-α) from stimulated peripheral immune cells, which in turn stimulate different levels of the HPA axis. Controversy exists regarding the main locus of action of endotoxin on glucocorticoid secretion, since the effect of endotoxin on this neuro-endocrine axis has been observed in intact animals and after ablation of the hypothalamus; however, a lack of LPS effect has been described at both pituitary and adrenocortical levels. The resulting increase in adrenal glucocorticoids has well-documented inhibitory effects on the inflammatory process and on inflammatory cytokine release. Therefore, immune activation of the adrenal gland by endotoxin is thought to occur by cytokine stimulation of corticosteroid-releasing hormone (CRH) production in the median eminence of the hypothalamus, which, in turn stimulates the secretion of ACTH from the pituitary. Acute administration of endotoxin stimulates ACTH and cortisol secretion and the release of CRH and vasopressin (AVP) in the hypophysial portal blood. During repeated endotoxemia, tolerance of both immune and HPA function develops, with a crucial role for glucocorticoids in the modulation of the HPA axis. A single exposure to a high dose of LPS can induce a long-lasting state of tolerance to a second exposure of LPS, affecting the response of plasma TNF-α and HPA hormones. Although there are gender differences in the HPA response to endotoxin and IL-1, these responses are enhanced by castration and attenuated by androgen and estrogen replacement. Estrogens attenuate the endotoxin-induced stimulation of IL-6, TNF-α and IL-1ra release and subsequent activation in postmenopausal women. There appears to be a temporal and functional relation between the HPA-axis response to endotoxin and nitric oxide formation in the neuro-endocrine hypothalamus, suggesting a stimulatory role for nitric oxide in modulating the HPA response to immune challenges.

References

Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993; 329: 1246—1253.

Besedovsky HO , del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17: 64—102.

Bertok L. Endotoxins and endocrine system.

Domest Anim

Endocrinol 1998; 15: 305—308.

Elenkov IJ , Kiss J. , Stark E. , Bertok L. CRF-dependent and CRFindependent mechanisms involved in hypophysial-adrenal system activation by bacterial endotoxin. Acta Physiol Hung 1992; 79: 355—363.

Elenkov IJ , Kovacs K. , Kiss J. , Bertok L. , Vizi ES Lipopolysaccharide is able to bypass corticotropin-releasing factor in affecting plasma ACTH and corticosterone levels: evidence from rats with lesions of the paraventricular nucleus. J Endocrinol 1992; 133: 231—236.

Revhaug A. , Michie HR , Manson JM et al. Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 1988; 123: 162—170.

Zabel P. , Wolter DT , Schonharting MM , Schade UF Oxpentifylline in endotoxaemia. Lancet 1989 ; 2: 1474—1477.

Pollmacher T. , Schreiber W. , Gudewill S. et al. Influence of endotoxin on nocturnal sleep in humans. Am J Physiol 1993; 264: R1077—R1083.

Suffredini AF , Reda D. , Banks SM , Tropea M. , Agosti JM , Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration . J Immunol 1995; 155: 5038—5045.

10.

Wexler BC , Dolgin AE , Tryczynski EW Effects of a bacterial polysaccharide (Piromen) on the pituitary-adrenal axis: adrenal ascorbic acid, cholesterol and histologic alterations. Endocrinology 1957; 61: 300—308.

11.

Perdrizet GA Hans Selye and beyond: response to stress. Cell Stress Chaperones 1997; 2: 214—219.

12.

Antoni FA Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 1986; 7: 351—378.

13.

Whitnall MH , Mezey E. , Gainer H. Co-localization of corticotropin-releasing factor and vasopressin in median eminence neurosecretory vesicles. Nature 1985; 317: 248—250.

14.

Munck A. , Guyre PM , Holbrook NJ Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984; 5: 25—44.

15.

Turnbull AV , Rivier CL Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79: 1—71.

16.

McEwen BS , Biron CA , Brunson KW et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev 1997; 23: 79—133.

17.

Sapolsky RM , Romero LM , Munck AU How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions . Endocr Rev 2000; 21: 55—89.

18.

Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 1991; 20: 697—720.

19.

Siiteri PK , Murai JT , Hammond GL , Nisker JA , Raymoure WJ , Kuhn RW The serum transport of steroid hormones. Recent Prog Horm Res 1982; 38: 457—510.

20.

Fleshner M. , Deak T. , Spencer RL , Laudenslager ML , Watkins LR , Maier SF A long-term increase in basal levels of corticosterone and a decrease in corticosteroid-binding globulin after acute stressor exposure . Endocrinology 1995; 136: 5336—5342.

21.

Neufeld JH , Breen L. , Hauger R. Extreme posture elevates corticosterone in a forced ambulation model of chronic stress in rats. Pharmacol Biochem Behav 1994 ; 47: 233—240.

22.

Garrel DR Corticosteroid-binding globulin during inflammation and burn injury: nutritional modulation and clinical implications. Horm Res 1996; 45: 245—251.

23.

Zouaghi H. , Savu L. , Guerot C. , Gryman R. , Coulon A. , Nunez EA Total and unbound cortisol-, progesterone-, oestrone- and transcortin-binding activities in sera from patients with myocardial infarction: evidence for differential responses of good and bad prognostic cases. Eur J Clin Invest 1985; 15: 365—370.

24.

Bernier J. , Jobin N. , Emptoz-Bonneton A. , Pugeat MM , Garrel DR Decreased corticosteroid-binding globulin in burn patients: relationship with interleukin-6 and fat in nutritional support. Crit Care Med 1998; 26: 452—460.

25.

Pemberton PA , Stein PE , Pepys MB , Potter JM , Carrell RW Hormone binding globulins undergo serpin conformational change in inflammation. Nature 1988; 336: 257—258.

26.

Beishuizen A. , Thijs LG , Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001; 27: 1584—1591.

27.

Hammond GL , Smith CL , Paterson NA , Sibbald WJ A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990; 71: 34—39.

28.

Ebeling P. , Koivisto VA Physiological importance of dehydroepiandrosterone. Lancet 1994; 343: 1479—1481.

29.

Regelson W. , Loria R. , Kalimi M. Dehydroepiandrosterone (DHEA) — the `mother steroid'. I. Immunologic action. Ann NY Acad Sci 1994; 719: 553—563.

30.

Regelson W. , Kalimi M.

Dehydroepiandrosterone (DHEA) — the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action?

Ann NY Acad Sci 1994; 719: 564—575.

31.

Bamberger CM , Schulte HM , Chrousos GP Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996; 17: 245—261.

32.

O'Connor TM , O'Halloran DJ , Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM 2000 ; 93: 323—333.

33.

McKay LI , Cidlowski JA Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999; 20: 435—459.

34.

McDonald PP , Cassatella MA Activation of transcription factor NF-kappaB by phagocytic stimuli in human neutrophils. FEBS Lett 1997; 412: 583—586.

35.

Leshin LS , Malven PV Bacteremia-induced changes in pituitary hormone release and effect of naloxone . Am J Physiol 1984; 247: E585—E591.

36.

Rivier C. , Chizzonite R. , Vale W. In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1. Endocrinology 1989; 125: 2800—2805.

37.

DeRijk R. , van Rooijen N. , Tilders FJ , Besedovsky HO , del Rey A. , Berkenbosch F. Selective depletion of macrophages prevents pituitary-adrenal activation in response to subpyrogenic, but not to pyrogenic, doses of bacterial endotoxin in rats. Endocrinology 1991; 129: 330—338.

38.

Schotanus K. , Makara GB , Tilders FJ , Berkenbosch F. ACTH response to a low dose but not a high dose of bacterial endotoxin in rats is completely mediated by corticotropin-releasing hormone. Neuroimmunomodulation 1994; 1: 300—307.

39.

Moberg GP Site of action of endotoxins on hypothalamic-pituitary-adrenal axis. Am J Physiol 1971; 220: 397—400.

40.

Rivier C. Role of endotoxin and interleukin-1 in modulating ACTH, LH and sex steroid secretion. Adv Exp Med Biol 1990; 274: 295—301.

41.

Suzuki S. , Oh C. , Nakano K. Pituitary-dependent and- independent secretion of CS caused by bacterial endotoxin in rats. Am J Physiol 1986; 250: E470—E474.

42.

Perlstein RS , Whitnall MH , Abrams JS , Mougey EH , Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo . Endocrinology 1993; 132: 946—952.

43.

Zuckerman SH , Shellhaas J. , Butler LD Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 1989; 19: 301—305.

44.

Sternberg EM , Hill JM , Chrousos GP et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989; 86: 2374—2378.

45.

Suzuki S. , Nakano K. LPS-caused secretion of corticosterone is mediated by histamine through histidine decarboxylase. Am J Physiol 1986; 250: E243—E247.

46.

Elin RJ , Wolff SM , McAdam KP et al. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 1981; 144: 329—336.

47.

Hochstein HD , Fitzgerald EA , McMahon FG , Vargas R. Properties of US standard endotoxin (EC-5) in human male volunteers. J Endotoxin Res 1994; 1: 52—56.

48.

Vedder H. , Schreiber W. , Yassouridis A. , Gudewill S. , Galanos C. , Pollmacher T. Dose-dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune-endocrine host response in humans. Inflamm Res 1999; 48: 67—74.

49.

Ottaway CA , Fong IW , da Silva B. , Singer W. , Karrass L. Integrative aspects of a human model of endotoxemia. Can J Physiol Pharmacol 1998; 76: 473—478.

50.

Schreiber W. , Pollmacher T. , Fassbender K. et al. Endotoxin- and corticotropin-releasing hormone-induced release of ACTH and cortisol. A comparative study in men. Neuroendocrinology 1993; 58: 123—128.

51.

Schuld A. , Mullington J. , Friess E. et al. Changes in dehydroepiandrosterone (DHEA) and DHEA-sulfate plasma levels during experimental endotoxinemia in healthy volunteers. J Clin Endocrinol Metab 2000; 85: 4624—4629.

52.

Puder JJ , Freda PU , Goland RS , Wardlaw SL Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab 2001; 86: 2403—2408.

53.

Pollmacher T. , Mullington J. , Korth C. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis 1996; 174: 1040—1045.

54.

Chong KT , Huston M. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of Gram-negative sepsis. J Infect Dis 1987; 156: 713—719.

55.

Moeniralam HS , Endert E. , van Lanschot JJ , Sauerwein HP , Romijn JA Blunted cortisol response after administration of corticotropin releasing hormone in endotoxemic dogs. J Endocrinol Invest 1997; 20: 476—481.

56.

Morrow LE , McClellan JL , Conn CA , Kluger MJ Glucocorticoids alter fever and IL-6 responses to psychological stress and to lipopolysaccharide. Am J Physiol 1993; 264: R1010—R1016.

57.

Coelho MM , Souza GE , Pela IR Endotoxin-induced fever is modulated by endogenous glucocorticoids in rats . Am J Physiol 1992; 263: R423—R427.

58.

Bertini R. , Bianchi M. , Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167: 1708—1712.

59.

Barber AE , Coyle SM , Marano MA et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999—2006.

60.

Santos AA , Scheltinga MR , Lynch E. et al. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 1993; 128: 138—143.

61.

Bamberger CM , Chrousos GP The glucocorticoid receptor and RU 486 in man. Ann NY Acad Sci 1995; 761: 296—310.

62.

Koo DJ , Jackman D. , Chaudry IH , Wang P. Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 2001; 29: 618—622.

63.

Hawes AS , Rock CS , Keogh CV , Lowry SF , Calvano SE In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect Immun 1992; 60: 2641—2647.

64.

Takemura T. , Makino S. , Takao T. , Asaba K. , Suemaru S. , Hashimoto K. Hypothalamic-pituitary-adrenocortical responses to single vs. repeated endotoxin lipopolysaccharide administration in the rat. Brain Res 1997; 767: 181—191.

65.

Takao T. , Hashimoto K. , De Souza EB Interleukin-1 receptors in the brain-endocrine-immune axis. Modulation by stress and infection. Ann NY Acad Sci 1995 ; 771: 372—385.

66.

Michie HR , Majzoub JA , O'Dwyer ST , Revhaug A. , Wilmore DW Both cyclooxygenase-dependent and cyclooxygenase-independent pathways mediate the neuroendocrine response in humans. Surgery 1990; 108: 254—259.

67.

Girardin E. , Grau GE , Dayer JM , Roux-Lombard P. , Lambert PH Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397—400.

68.

Kakucska I. , Qi Y. , Clark BD , Lechan RM Endotoxin-induced corticotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is mediated centrally by interleukin-1. Endocrinology 1993; 133: 815—821.

69.

Givalois L. , Siaud P. , Mekaouche M. et al. Early hypothalamic activation of combined Fos and CRH41 immunoreactivity and of CRH41 release in push-pull cannulated rats after systemic endotoxin challenge. Mol Chem Neuropathol 1995; 26: 171—186.

70.

Yasuda N. , Greer MA Evidence that the hypothalamus mediates endotoxin stimulation of adrenocorticotropic hormone secretion. Endocrinology 1978; 102: 947—953.

71.

Roh MS , Drazenovich KA , Barbose JJ , Dinarello CA , Cobb CF Direct stimulation of the adrenal cortex by interleukin-1. Surgery 1987; 102: 140—146.

72.

Whitcomb RW , Linehan WM , Wahl LM , Knazek RA Monocytes stimulate cortisol production by cultured human adrenocortical cells. J Clin Endocrinol Metab 1988; 66: 33—38.

73.

Bernton EW , Beach JE , Holaday JW , Smallridge RC , Fein HG Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 1987; 238: 519—521.

74.

Malarkey WB , Zvara BJ Interleukin-1 beta and other cytokines stimulate adrenocorticotropin release from cultured pituitary cells of patients with Cushing's disease. J Clin Endocrinol Metab 1989; 69: 196—199.

75.

Makara GB , Stark E. , Meszaros T. Corticotrophin release induced by E. coli endotoxin after removal of the medial hypothalamus. Endocrinology 1971; 88: 412—414.

76.

Spinedi E. , Suescun MO , Hadid R. , Daneva T. , Gaillard RC Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal axis: evidence for a neuroendocrine-immunological sexual dimorphism. Endocrinology 1992; 131: 2430—2436.

77.

Hadid R. , Spinedi E. , Daneva T. , Grau G. , Gaillard RC Repeated endotoxin treatment decreases immune and hypothalamo-pituitary- adrenal axis responses: effects of orchidectomy and testosterone therapy. Neuroendocrinology 1995; 62: 348—355.

78.

West MA , Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002; 30: S64—S73.

79.

Elenkov IJ , Hasko G. , Kovacs KJ , Vizi ES Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol 1995; 61: 123—131.

80.

Hasko G. , Elenkov IJ , Kvetan V. , Vizi ES Differential effect of selective block of alpha 2-adrenoreceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol 1995; 144: 457—462.

81.

Chautard T. , Spinedi E. , Voirol M. , Pralong FP , Gaillard RC Role of glucocorticoids in the response of the hypothalamocorticotrope, immune and adipose systems to repeated endotoxin administration. Neuroendocrinology 1999; 69: 360—369.

82.

Hadid R. , Spinedi E. , Giovambattista A. , Chautard T. , Gaillard RC Decreased hypothalamo-pituitary-adrenal axis response to neuroendocrine challenge under repeated endotoxemia. Neuroimmunomodulation 1996; 3: 62—68.

83.

Grinevich V. , Ma XM , Herman JP , Jezova D. , Akmayev I. , Aguilera G. Effect of repeated lipopolysaccharide administration on tissue cytokine expression and hypothalamic-pituitary-adrenal axis activity in rats. J Neuroendocrinol 2001; 13: 711—723.

84.

Nobel CS , Schultzberg M. Induction of interleukin-1 beta mRNA and enkephalin mRNA in the rat adrenal gland by lipopolysaccharides studied by in situ hybridization histochemistry . Neuroimmunomodulation 1995; 2: 61—73.

85.

Nagano I. , Takao T. , Nanamiya W. , Hashimoto K. Modulation of type I interleukin-1 receptor messenger RNA followed by one and repeated endotoxin treatment in the mouse. J Neuroimmunol 2000; 105: 154—160.

86.

Bornstein SR , Chrousos GP Clinical review 104: Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999; 84: 1729—1736.

87.

Giovambattista A. , Chisari AN , Corro L. , Gaillard RC , Spinedi E. Metabolic, neuroendocrine and immune functions in basal conditions and during the acute-phase response to endotoxic shock in undernourished rats. Neuroimmunomodulation 2000; 7: 92—98.

88.

Gaillard RC , Spinedi E. Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunological sexual dimorphism . Domest Anim Endocrinol 1998; 15: 345—352.

89.

Daneva T. , Spinedi E. , Hadid R. , Gaillard RC Impaired hypothalamo-pituitary-adrenal axis function in Swiss nude athymic mice. Neuroendocrinology 1995; 62: 79—86.

90.

Harbuz MS , Rooney C. , Jones M. , Ingram CD Hypothalamo-pituitary-adrenal axis responses to lipopolysaccharide in male and female rats with adjuvant-induced arthritis. Brain Behav Immun 1999; 13: 335—347.

91.

Vamvakoupulos NC , Chrousos GP Evidence of direct regulation of human corticotropin releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. J Clin Invest 1993; 92: 1896—1902.

92.

Shanks N. , Meaney MJ Hypothalamic-pituitary-adrenal activation following endotoxin administration in the developing rat: a CRH-mediated effect. J Neuroendocrinol 1994; 6: 375—383.

93.

Guillet R. , Saffran M. , Michaelson SM Pituitary-adrenal response in neonatal rats. Endocrinology 1980; 106: 991—994.

94.

Dent GW , Smith MA , Levine S. The ontogeny of the neuroendocrine response to endotoxin. Brain Res Dev Brain Res 1999; 117: 21—29.

95.

Elmquist JK , Ackermann MR , Register KB , Rimler RB , Ross LR , Jacobson CD Induction of Fos-like immunoreactivity in the rat brain following Pasteurella multocida endotoxin administration. Endocrinology 1993; 133: 3054—3057.

96.

Witek-Janusek L. Pituitary-adrenal response to bacterial endotoxin in developing rats. Am J Physiol 1988; 255: E525—E530.

97.

Blalock JE , Smith EM A complete regulatory loop between the immune and neuroendocrine systems. Fed Proc 1985; 44: 108—111.

98.

Barnes PJ , Greening AP , Crompton GK Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995; 152: S125-S140.

99.

Molijn GJ , Spek JJ , van Uffelen JC et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995; 80: 1799—1803.

100.

Molijn GJ , Koper JW , van Uffelen CJ et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leukocyte in patients with sepsis or septic shock. Clin Endocrinol (Oxf) 1995; 43: 197—203.

101.

Meduri GU , Tolley EA , Chrousos GP , Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165: 983—991.

102.

Reincke M. , Allolio B. , Wurth G. , Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone . J Clin Endocrinol Metab 1993; 77: 151—156.

103.

Schroeder S. , Wichers M. , Klingmuller D. et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001; 29: 310—316.

104.

Weidenfeld J. , Yirmiya R. Effects of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress. Neuroimmunomodulation 1996; 3: 352—357.

105.

Tornello S. , Orti E. , De Nicola AF , Rainbow TC , McEwen BS Regulation of glucocorticoid receptors in brain by corticosterone treatment of adrenalectomized rats. Neuroendocrinology 1982; 35: 411—417.

106.

Schobitz B. , Sutanto W. , Carey MP , Holsboer F. , de Kloet ER Endotoxin and interleukin 1 decrease the affinity of hippocampal mineralocorticoid (type I) receptor in parallel to activation of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology 1994; 60: 124—133.

107.

Betancur C. , Borrell J. , Guaza C. Cytokine regulation of corticosteroid receptors in the rat hippocampus: effects of interleukin-1, interleukin-6, tumor necrosis factor and lipopolysaccharide. Neuroendocrinology 1995; 62: 47—54.

108.

Vermes I. , Beishuizen A. , Hampsink RM , Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995; 80: 1238—1242.

109.

Chrousos GP The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351—1362.

110.

Leung DY , Hmid Q. , Vottero A. et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. J Exp Med 1997; 186: 1567—1574.

111.

Bollaert PE , Charpentier C. , Levy B. , Debouverie M. , Audibert G. , Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone . Crit Care Med 1998; 26: 645—650.

112.

Spencer RL , Miller AH , Stein M. , McEwen BS Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue. Brain Res 1991; 549: 236—246.

113.

Parker LN , Levin ER , Lifrak ET Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985; 60: 947—952.

114.

Wade CE , Lindberg JS , Cockrell JL et al. Upon-admission adrenal steroidogenesis is adapted to the degree of illness in intensive care unit patients. J Clin Endocrinol Metab 1988; 67: 223—227.

115.

Luppa P. , Munker R. , Nagel D. , Weber M. , Engelhardt D. Serum androgens in intensive-care patients: correlations with clinical findings . Clin Endocrinol (Oxf) 1991; 34: 305—310.

116.

Lephart ED , Baxter CR , Parker Jr CR Effect of burn trauma on adrenal and testicular steroid hormone production. J Clin Endocrinol Metab 1987; 64: 842—848.

117.

Spratt DI , Longcope C. , Cox PM , Bigos ST , Wilbur-Welling C. Differential changes in serum concentrations of androgens and estrogens (in relation with cortisol) in postmenopausal women with acute illness. J Clin Endocrinol Metab 1993; 76: 1542—1547.

118.

Araneo B. , Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology 1995; 136: 393—401.

119.

Araneo BA , Shelby J. , Li GZ , Ku W. , Daynes RA Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence. Arch Surg 1993; 128: 318—325.

120.

Danenberg HD , Alpert G. , Lustig S. , Ben Nathan D. Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother 1992; 36: 2275—2279.

121.

Oberbeck R. , Dahlweid M. , Koch R. et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med 2001; 29: 380—384.

122.

Schurr MJ , Fabian TC , Croce MA , Varnavas LE , Proctor KG Dehydroepiandrosterone, an endogenous immune modulator, after traumatic shock . Shock 1997; 7: 55—59.

123.

Bornstein SR , Wolkersdorfer GW , Tauchnitz R. , Preas HL , Chrousos GP , Suffredini AF Plasma dehydroepiandrosterone levels during experimental endotoxemia and anti-inflammatory therapy in humans. Crit Care Med 2000; 28: 2103—2106.

124.

Straub RH , Konecna L. , Hrach S. et al. Serum DHEA and DHEAS are negatively correlated with serum IL-6, and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocr Metab 1998; 83: 2012—2017.

125.

Berkenbosch F. , de Goeij DE , Rey AD , Besedovsky HO Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. Neuroendocrinology 1989; 50: 570—576.

126.

Ebisui O. , Fukata J. , Murakami N. et al. Effect of IL-1 receptor antagonist and antiserum to TNF-alpha on LPS- induced plasma ACTH and corticosterone rise in rats. Am J Physiol 1994; 266: E986—E992.

127.

Sapolsky R. , Rivier C. , Yamamoto G. , Plotsky P. , Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin- releasing factor. Science 1987; 238: 522—524.

128.

Uehara A. , Gottschall PE , Dahl RR , Arimura A. Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 1987; 121: 1580—1582.

129.

Sharp BM , Matta SG , Peterson PK , Newton R. , Chao C. , McAllen K. Tumor necrosis factor-alpha is a potent ACTH secretagogue: comparison to interleukin-1 beta. Endocrinology 1989; 124: 3131—3133.

130.

Quan N. , Whiteside M. , Herkenham M. Time course and localization patterns of interleukin-1 beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide . Neuroscience 1998; 83: 281—293.

131.

Tilders FJ , Derijk RH , Van Dam AM , Vincent VA , Schotanus K. , Persoons JH Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology 1994; 19: 209—232.

132.

Wilckens T. , de Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997; 18: 418—424.

133.

Boumpas DT , Chrousos GP , Wilder RL , Cupps TR , Balow JE Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119: 1198—1208.

134.

O' Conner TM , O'Halloran DJ , Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM 2000 ; 93: 323—333.

135.

Berkenbosch F. , van Oers J. , del Rey A. , Tilders F. , Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238: 524—526.

136.

Spinedi E. , Hadid R. , Daneva T. , Gaillard RC Cytokines stimulate the CRH but not the vasopressin neuronal system: evidence for a median eminence site of interleukin-6 action . Neuroendocrinology 1992; 56: 46—53.

137.

138.

Navarra P. , Pozzoli G. , Becherucci C. , Preziosi P. , Grossman AB , Parente L. Prostaglandin E2 and bacterial lipopolysaccharide stimulate bioactive interleukin-1 release from rat hypothalamic explants. Neuroendocrinology 1993; 57: 257—261.

139.

Spangelo BL , Judd AM , MacLeod RM , Goodman DW , Isakson PC Endotoxin-induced release of interleukin-6 from rat medial basal hypothalami. Endocrinology 1990; 127: 1779—1785.

140.

Bernardini R. , Kamilaris TC , Calogero AE et al. Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990; 126: 2876—2881.

141.

Gaillard RC , Turnill D. , Sappino P. , Muller AF Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990; 127: 101—106.

142.

Besedovsky H. , del Rey A. , Sorkin E. , Dinarello CA Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233: 652—654.

143.

Koenig JI , Snow K. , Clark BD et al. Intrinsic pituitary interleukin-1 beta is induced by bacterial lipopolysaccharide. Endocrinology 1990; 126: 3053—3058.

144.

Brunetti L. , Preziosi P. , Ragazzoni E. , Vacca M. Effects of lipopolysaccharide on hypothalamic-pituitary-adrenal axis in vitro. Life Sci 1994; 54: L165—L171.

145.

Dinarello CA Interleukin-1 and interleukin-1 antagonism . Blood 1991; 77: 1627—1652.

146.

Kobayashi H. , Fukata J. , Tominaga T. et al. Regulation of interleukin-1 receptors on AtT-20 mouse pituitary tumour cells. FEBS Lett 1992; 298: 100—104.

147.

Takao T. , Mitchell WM , De Souza EB Interleukin-1 receptors in mouse kidney: identification, localization, and modulation by lipopolysaccharide treatment. Endocrinology 1991; 128: 2618—2624.

148.

van der Meer MJ , Sweep CG , Rijnkels CE et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1 beta, TNF alpha and IL-6: a dose response study. J Endocrinol Invest 1996; 19: 175—182.

149.

Schotanus K. , Tilders FJ , Berkenbosch F. Human recombinant interleukin-1 receptor antagonist prevents adrenocorticotropin, but not interleukin-6 responses to bacterial endotoxin in rats. Endocrinology 1993; 133: 2461—2468.

150.

Schotanus K. , Meloen RH , Puijk WC , Berkenbosch F. , Binnekade R. , Tilders FJ Effects of monoclonal antibodies to specific epitopes of rat interleukin-1 beta (IL-1 beta) on IL-1 beta-induced ACTH, corticosterone and IL-6 responses in rats. J Neuroendocrinol 1995; 7: 255—262.

151.

Lenczowski MJ , Van Dam AM , Poole S. , Larrick JW , Tilders FJ Role of circulating endotoxin and interleukin-6 in the ACTH and corticosterone response to intraperitoneal LPS. Am J Physiol 1997; 273: R1870—R1877.

152.

Van Zee KJ , Coyle SM , Calvano SE et al. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol 1995; 154: 1499—1507.

153.

Mazzocchi G. , Gottardo G. , Nussdorfer GG A local immunoendocrine interaction may mediate rat adrenal glucocorticoid response to bacterial endotoxins. Life Sci 1998; 62: 1783—1787.

154.

Eskay RL , Grino M. , Chen HT Interleukins, signal transduction, and the immune system-mediated stress response . Adv Exp Med Biol 1990; 274: 331—343.

155.

Naitoh Y. , Fukata J. , Tominaga T. et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun 1988; 155: 1459—1463.

156.

Mastorakos G. , Chrousos GP , Weber JS Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993 ; 77: 1690—1694.

157.

Beishuizen A. , Vermes I. , Haanen C. Endogenous mediators in sepsis and septic shock. Adv Clin Chem 1998; 33: 55—131.

158.

Ehrhart-Bornstein M. , Hinson JP , Bornstein SR , Scherbaum WA , Vinson GP Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998; 19: 101—143.

159.

Path G. , Bornstein SR , Ehrhart-Bornstein M. , Scherbaum WA Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82: 2343—2349.

160.

Spath-Schwalbe E. , Born J. , Schrezenmeier H. et al. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994; 79: 1212—1214.

161.

Ruzek MC , Miller AH , Opal SM , Pearce BD , Biron CA Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 1997; 185: 1185—1192.

162.

Papanicolaou DA , Wilder RL , Manolagas SC , Chrousos GP The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127—137.

163.

Spangelo BL , Judd AM , Isakson PC , MacLeod RM. Interleukin-1 stimulates interleukin-6 release from rat anterior pituitary cells in vitro. Endocrinology 1991; 128: 2685—2692.

164.

Spangelo BL , MacLeod RM. Immunopeptide regulation of anterior pituitary function. Int J Neurosci 1990; 51: 369—370.

165.

Vallieres L. , Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology 1999; 140: 3890—3903.

166.

Muglia LJ , Bethin KE , Jacobson L. , Vogt SK , Majzoub JA Pituitary-adrenal axis regulation in CRH-deficient mice. Endocr Res 2000; 26: 1057—1066.

167.

Bethin KE , Vogt SK , Muglia LJ Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 2000; 97: 9317—9322.

168.

Path G. , Scherbaum WA , Bornstein SR The role of interleukin-6 in the human adrenal gland. Eur J Clin Invest 2000; 30 (Suppl 3): 91—95.

169.

Fattori E. , Cappelletti M. , Costa P. et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994 ; 180: 1243—1250.

170.

Hadid R. , Spinedi E. , Chautard T. , Giacomini M. , Gaillard RC Role of several mediators of inflammation on the mouse hypothalamo-pituitary-adrenal axis response during acute endotoxemia. Neuroimmunomodulation 1999; 6: 336—343.

171.

Derijk R. , Van Rooijen N. , Tilders FJ , Besedovsky HO , del Rey A. , Berkenbosch F. Selective depletion of macrophages prevents pituitary-adrenal activation in response to subpyrogenic, but not to pyrogenic, doses of bacterial endotoxin in rats. Endocrinology 1991; 129: 330—338.

172.

Mengozzi M. , Ghezzi P. Cytokine down-regulation in endotoxin tolerance . Eur Cytokine Netw 1993; 4: 89—98.

173.

Lenczowski MJ , Schmidt ED , Van Dam AM , Gaykema RP , Tilders FJ Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Ann NY Acad Sci 1998; 856: 139—147.

174.

Dunn AJ The role of interleukin-1 and tumor necrosis factor alpha in the neurochemical and neuroendocrine responses to endotoxin. Brain Res Bull 1992; 29: 807—812.

175.

Harbuz MS , Stephanou A. , Sarlis N. , Lightman SL The effects of recombinant human interleukin (IL)-1 alpha, IL-1 beta or IL-6 on hypothalamo-pituitary-adrenal axis activation. J Endocrinol 1992; 133: 349—355.

176.

Schein M. , Wittmann DH , Holzheimer R. , Condon RE Hypothesis: compartmentalization of cytokines in intraabdominal infection . Surgery 1996; 119: 694—700.

177.

Neta R. , Perlstein R. , Vogel SN , Ledney GD , Abrams J. Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med 1992; 175: 689—694.

178.

Ericsson A. , Kovacs KJ , Sawchenko PE A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 1994; 14: 897—913.

179.

Takao T. , Tojo C. , Nishioka T. et al. Reciprocal modulation of corticotropin-releasing factor and interleukin-1 receptors following ether-laparotomy stress in the mouse. Brain Res 1994; 660: 170—174.

180.

Wang Z. , Ren SG , Melmed S. Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology 1996; 137: 2947—2953.

181.

Bernhagen J. , Calandra T. , Mitchell RA et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756—759.

182.

Fong Y. , Moldawer LL , Marano M. et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 1989; 142: 2321—2324.

183.

Yamaguchi M. , Matsuzaki N. , Hirota K. , Miyake A. , Tanizawa O. Interleukin 6 possibly induced by interleukin 1 beta in the pituitary gland stimulates the release of gonadotropins and prolactin. Acta Endocrinol (Copenh) 1990 ; 122: 201—205.

184.

Wang MH , Flad HD , Feist W. et al. Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells. Infect Immun 1991; 59: 4655—4664.

185.

Warren HS , Novitsky TJ , Ketchum PA , Roslansky PF , Kania S. , Siber GR Neutralization of bacterial lipopolysaccharides by human plasma. J Clin Microbiol 1985; 22: 590—595.

186.

Greisman SE , Young EJ , Carozza Jr FA. Mechanisms of endotoxin tolerance. V. Specificity of the early and late phases of pyrogenic tolerance. J Immunol 1969; 103: 1223—1236.

187.

Seckinger P. , Zhang JH , Hauptmann B. , Dayer JM Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990 ; 87: 5188—5192.

188.

Hannum CH , Wilcox CJ , Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336—340.

189.

Evans GF , Zuckerman SH Glucocorticoid-dependent and- independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 1991; 21: 1973—1979.

190.

Szabo C. , Thiemermann C. , Wu CC , Perretti M. , Vane JR Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 1994; 91: 271—275.

191.

Mengozzi M. , Ghezzi P. Defective tolerance to the toxic and metabolic effects of interleukin 1. Endocrinology 1991 ; 128: 1668—1672.

192.

Metcalf D. Leukemia inhibitory factor — a puzzling polyfunctional regulator. Growth Factors 1992 ; 7: 169—173.

193.

Patterson PH Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology. Proc Natl Acad Sci USA 1994; 91: 7833—7835.

194.

Auernhammer CJ , Melmed S. Leukemia-inhibitory factorneuroimmune modulator of endocrine function. Endocr Rev 2000; 21: 313—345.

195.

Waring PM , Waring LJ , Metcalf D. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis 1994; 170: 1224—1228.

196.

Waring PM , Waring LJ , Billington T. , Metcalf D. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc Natl Acad Sci USA 1995; 92: 1337—1341.

197.

Chesnokova V. , Auernhammer CJ , Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998; 139: 2209—2216.

198.

Akita S. , Malkin J. , Melmed S. Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. Endocrinology 1996 ; 137: 3140—3143.

199.

Ren SG , Seliktar J. , Li X. , Braunstein GD , Melmed S. Measurement of leukemia inhibitory factor in biological fluids by radioimmunoassay . J Clin Endocrinol Metab 1998; 83: 1275—1283.

200.

Akita S. , Conn PM , Melmed S. Leukemia inhibitory factor (LIF) induces acute adrenocorticotrophic hormone (ACTH) secretion in fetal rhesus macaque primates: a novel dynamic test of pituitary function. J Clin Endocrinol Metab 1996; 81: 4170—4178.

201.

Chesnokova V. , Melmed S. Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflammation. Endocrinology 2000; 141: 4032—4040.

202.

Calandra T. , Bernhagen J. , Mitchell RA , Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895—1902.

203.

Bucala R. MIF, a previously unrecognized pituitary hormone and macrophage cytokine, is a pivotal mediator in endotoxic shock. Circ Shock 1994; 44: 35—39.

204.

Bernhagen J. , Calandra T. , Cerami A. , Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends Microbiol 1994; 2: 198—201.

205.

Fingerle-Rowson GR , Bucala R. Neuroendocrine properties of macrophage migration inhibitory factor (MIF). Immunol Cell Biol 2001; 79: 368—375.

206.

Nishino T. , Bernhagen J. , Shiiki H. , Calandra T. , Dohi K. , Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995 ; 1: 781—788.

207.

Bacher M. , Meinhardt A. , Lan HY et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 1997; 150: 235—246.

208.

Bucala R. MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. Cytokine Growth Factor Rev 1996; 7: 19—24.

209.

Calandra T. , Bernhagen J. , Metz CN et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68—71.

210.

Judd AM Cytokine expression in the rat adrenal cortex. Horm Metab Res 1998; 30: 404—410.

211.

Mazzocchi G. , Rocco S. , Malendowicz LK , Rebuffat P. , Nussdorfer GG Bacterial lipopolysaccharide stimulates glucocorticoid secretion in hypophysectomized rats. Endocr Res 1995; 21: 525—536.

212.

Kjaer A. , Larsen PJ , Knigge U. , Warberg J. Histaminergic activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 1994; 135: 1171—1177.

213.

Spinedi E. , Negro-Vilar A. Serotonin and adrenocorticotropin (ACTH) release: direct effects at the anterior pituitary level and potentiation of arginine vasopressin-induced ACTH release. Endocrinology 1983; 112: 1217—1223.

214.

Spinedi E. , Johnston CA , Chisari A. , Negro-Vilar A. Role of central epinephrine on the regulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocrinology 1988; 122: 1977—1983.

215.

Hargreaves KM , Costello AH , Joris JL Release from inflamed tissue of a substance with properties similar to corticotropin-releasing factor. Neuroendocrinology 1989; 49: 476—482.

216.

Rivier C. , Vale W.

Stimulatory effect of interleukin-1 on adrenocorticotropin secretion in the rat: is it modulated by prostaglandins?

Endocrinology 1991; 129: 384—388.

217.

Ichitani Y. , Holmberg K. , Maunsbach AB et al. Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies. Cell Tissue Res 2001; 303: 235—252.

218.

Parrott RF , Vellucci SV , Goode JA , Lloyd DM , Forsling ML Cyclo-oxygenase mediation of endotoxin-induced fever, anterior and posterior pituitary hormone release, and hypothalamic c-Fos expression in the prepubertal pig. Exp Physiol 1995; 80: 663—674.

219.

Parrott RF , Vellucci SV , Goode JA , Lloyd DM , Forsling ML Interrelated adrenocortical and neurohypophysial responses associated with fever in endotoxin-treated pigs. Am J Physiol 1997; 273: R1046—R1052.

220.

Battaglia DF , Brown ME , Krasa HB , Thrun LA , Viguie C. , Karsch FJ Systemic challenge with endotoxin stimulates corticotropin-releasing hormone and arginine vasopressin secretion into hypophyseal portal blood: coincidence with gonadotropin-releasing hormone suppression . Endocrinology 1998; 139: 4175—4181.

221.

Dadoun F. , Velut JG , Guillaume V. et al. Combined hypervolemia and hypoosmolality alter hypothalamic-pituitary-adrenal axis response to endotoxin stimulation. Neuroendocrinology 1999; 69: 352—359.

222.

Whitnall MH , Perlstein RS , Mougey EH , Neta R. Effects of interleukin-1 on the stress-responsive and -nonresponsive subtypes of corticotropin-releasing hormone neurosecretory axons. Endocrinology 1992; 131: 37—44.

223.

Naito Y. , Fukata J. , Shindo K. et al. Effects of interleukins on plasma arginine vasopressin and oxytocin levels in conscious, freely moving rats. Biochem Biophys Res Commun 1991; 174: 1189—1195.

224.

Dadoun F. , Guillaume V. , Sauze N. et al. Effect of endotoxin on the hypothalamic-pituitary-adrenal axis in sheep. Eur J Endocrinol 1998; 138: 193—197.

225.

Leech M. , Metz C. , Bucala R. , Morand EF Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 827—833.

226.

Sarraf P. , Frederich RC , Turner EM et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997; 185: 171—175.

227.

Grunfeld C. , Zhao C. , Fuller J. et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152—2157.

228.

De Vos P. , Saladin R. , Auwerx J. , Staels B. Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 1995; 270: 15958—15961.

229.

Ahima RS , Prabakaran D. , Mantzoros C. et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250—252.

230.

Gaillard RC , Spinedi E. , Chautard T. , Pralong FP Cytokines, leptin, and the hypothalamo-pituitary-adrenal axis. Ann NY Acad Sci 2000; 917: 647—657.

231.

Lee S. , Rivier C. Altered ACTH and corticosterone responses to interleukin-1 beta in male rats exposed to an alcohol diet: possible role of vasopressin and testosterone . Alcohol Clin Exp Res 1995; 19: 200—208.

232.

Xia-Zhang L. , Xiao E. , Ferin M. A 5-day estradiol therapy, in amounts reproducing concentrations of the early-mid follicular phase, prevents the activation of the hypothalamo- pituitary-adrenal axis by interleukin-1 alpha in the ovariectomized rhesus monkey. J Neuroendocrinol 1995; 7: 387—392.

233.

Uribe RM , Lee S. , Rivier C. Endotoxin stimulates nitric oxide production in the paraventricular nucleus of the hypothalamus through nitric oxide synthase I: correlation with hypothalamic-pituitary-adrenal axis activation. Endocrinology 1999; 140: 5971—5981.

234.

Navarra P. , Tsagarakis S. , Faria MS , Rees LH , Besser GM , Grossman AB Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 1991; 128: 37—44.

235.

Kim CK , Rivier C. Influence of nitric oxide synthase inhibitors on the ACTH and cytokine responses to peripheral immune signals. J Neuroendocrinol 1998; 10: 353—362.

236.

Rivier C. , Shen GH In the rat, endogenous nitric oxide modulates the response of the hypothalamic-pituitary-adrenal axis to interleukin-1 beta, vasopressin, and oxytocin. J Neurosci 1994; 14: 1985—1993.

237.

Wong ML , Rettori V. , al Shekhlee A. et al. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med 1996 ; 2: 581—584.

238.

Schlechte JA , Hamilton D. The effect of glucocorticoids on corticosteroid binding globulin. Clin Endocrinol (Oxf) 1987; 27: 197—203.

239.

Beishuizen A. , Thijs LG , Haanen C. , Vermes I. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 2001; 86: 2811—2816.

240.

Naito Y. , Tamai S. , Shingu K. et al. Responses of plasma adrenocorticotropic hormone, cortisol, and cytokines during and after upper abdominal surgery. Anesthesiology 1992; 77: 426—431.

241.

Chikanza IC , Grossman AB Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Baillière's Clin Rheumatol 1996; 10: 199—225.

242.

Chikanza IC , Petrou P. , Kingsley G. , Chrousos G. , Panayi GS Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281—1288.

243.

Michelson D. , Stone L. , Galliven E. et al. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab 1994; 79: 848—853.

244.

Franchimont D. , Bouma G. , Galon J. et al. Adrenal cortical activation in murine colitis. Gastroenterology 2000; 119: 1560—1568.

245.

Lamberts SW , Bruining HA , de Jong FH Corticosteroid therapy in severe illness. N Engl J Med 1997; 337: 1285—1292.

246.

Beishuizen A. , Thijs LG

Relative adrenal failure in intensive care: an identifiable problem requiring treatment?

Best Pract Res Clin Endocrinol Metab 2001; 15: 513—531.

247.

Streeten DH Shortcomings in the low-dose (1 μg) ACTH test for the diagnosis of ACTH deficiency states. Clin Endocrinol Metab 1999; 84: 835—837.

248.

Zipser RD , Davenport MW , Martin KL et al. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab 1981; 53: 867—873.

249.

Findling JW , Waters VO , Raff H. The dissociation of renin and aldosterone during critical illness. J Clin Endocrinol Metab 1987; 64: 592—595.

250.

Vermes I. , Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 2001; 15: 495—511.

251.

Soni A. , Pepper GM , Wyrwinski PM et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995; 98: 266—271.

252.

Bouachour G. , Tirot P. , Gouello JP , Mathieu E. , Vincent JF , Alquier P. Adrenocortical function during septic shock . Intensive Care Med 1995; 21: 57—62.

253.

Zaloga GP , Marik P. Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin 2001; 17: 25—41.

254.

Keri G. , Parameswaran V. , Trunkey DD , Ramachandran J. Effects of septic shock plasma on adrenocortical cell function. Life Sci 1981; 28: 1917—1923.

255.

Jaattela M. , Ilvesmaki V. , Voutilainen R. , Stenman UH , Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991; 128: 623—629.

256.

Jaattela M. , Carpen O. , Stenman UH , Saksela E. Regulation of ACTH-induced steroidogenesis in human fetal adrenals by rTNFalpha . Mol Cell Endocrinol 1990; 68: R31—R36.

257.

Garcia R. , Abarca S. , Municio AM Adrenal gland function in reversible endotoxic shock. Circ Shock 1990; 30: 365—374.

258.

Garcia R. , Viloria MD , Municio AM Influence of E. coli endotoxin on ACTH induced adrenal cell steroidogenesis . J Steroid Biochem 1985; 22: 377—385.

259.

Lamberts SW , Bons EG , Zuiderwijk-van der Roest JM. Studies on the mechanism of corticotrophin-mediated desensitization of corticosterone secretion by rat adrenocortical cells. Mol Cell Endocrinol 1987; 52: 243—249.

260.

Imura H. , Fukata J. Endocrine-paracrine interaction in communication between the immune and endocrine systems. Activation of the hypothalamic-pituitary-adrenal axis in inflammation . Eur J Endocrinol 1994; 130: 32—37.

261.

Antoni FA Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993; 14: 76—122.

262.

Mastorakos G. , Weber JS , Magiakou MA , Gunn H. , Chrousos GP Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994; 79: 934—939.

263.

Ray DW , Ren SG , Melmed S. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996; 97: 1852—1859.

264.

Bousquet C. , Ray DW , Melmed S. A common proopiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. J Biol Chem 1997; 272: 10551—10557.

265.

Kapcala LP , Chautard T. , Eskay RL The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress . Ann NY Acad Sci 1995; 771: 419—437.

266.

Berczi I. Neurohormonal host defense in endotoxin shock. Ann NY Acad Sci 1998; 840: 787—802.

267.

Smith GW , Aubry JM , Dellu F. et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development . Neuron 1998; 20: 1093—1102.

268.

Karalis KP , Kontopoulos E. , Muglia LJ , Majzoub JA Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Proc Natl Acad Sci USA 1999; 96: 7093—7097.

269.

Timpl P. , Spanagel R. , Sillaber I. et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat Genet 1998; 19: 162—166.

270.

Matot I. , Sprung CL

Corticosteroids in septic shock: resurrection of the last rites?

Crit Care Med 1998; 26: 627—630.

271.

Annane D. , Sebille V. , Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862—871.

272.

Briegel J. , Forst H. , Haller M. et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723—732.

273.

Annane D. Replacement therapy with hydrocortisone in catecholamine-dependent septic shock. J Endotoxin Res 2001; 7: 305—309.